Clinical Trial Goal
To find out:
- The highest dose of ELVN-001 that’s safe to give
- If ELVN-001 is safe and works well to treat CML that has relapsed or is refractory
You may be able to join this trial if you:
- Are 18 years or older
- Have CML in chronic phase that has relapsed or is refractory
- Have not had a blood or marrow transplant in the last 5 moths
- Agree to have other standard tests done to see if you can be in the clinical trial
Trial Details
ELVN-001 is a small molecule inhibitor that blocks BCR-ABL in certain cells.
You'll get:
You'll get:
- ELVN-001 – A pill that you take by mouth 1-2 times each day. The dose you get depends on when you start the trial and how safe it has been
You may continue treatment for as long as doctors think is best for your health. You'll have biopsies to see how well the treatment is working. The clinical trial doctors will check your health for up to 3 years.
The Food and Drug Administration (FDA) has not yet approved ELVN-001.
Locations
Memorial Sloan Kettering Cancer CenterRECRUITING
New York, New York
Michael Mauro, MD, 347-798-9213
Montefiore Medical CenterRECRUITING
The Bronx, New York
David Levitz MD, 718-920-4321
Oregon Health & Science University-Knight Cardiovascular InstituteRECRUITING
Portland, Oregon
Michael Heinrich, MD, 503-418-1964
The University of Texas MD Anderson Cancer CenterRECRUITING
Houston, Texas
Fadi Haddad, MD, 877-632-6789
Sponsors
lead: Enliven Therapeutics
